Chris Boffi

MD, New York at Perella Weinberg Partners

Chris Boffi is a Managing Director in Perella Weinberg Partners’ advisory business. Mr. Boffi has extensive experience in regulated consumer segments, including cannabis, beverages and reduced-harm nicotine.

Representative transactions in cannabis include advising: Parallel on its strategic review and capital raise via senior secured notes; Schwazze on its placement of a $95M convertible note and acquisition of R. Greenleaf; Altria on Cronos’ minority investment in PharmaCann; and Altria on its investment in Cronos.

Representative transactions in beverages include advising: Altria on the sale of its 27% stake in SABMiller to ABI; City Brewing on its sale to Pabst Brewing Company; Castle Brands on its sale to Pernod Ricard; Heaven Hill on its acquisition of Deep Eddy Vodka; and Pabst Brewing Company on its sale to Eugene Kasper and TSG Consumer.

Representative transactions in reduced-harm nicotine and tobacco include advising: Altria on several assignments, including its acquisition of a majority stake in on! and acquisition of Nat Sherman; and the first lien creditors of Pyxus International during its Chapter 11 bankruptcy.

Chris has also advised other retail and consumer companies on a variety of M&A, shareholder activism and capital structure assignments. Representative transactions include advising: GameStop on its strategic review, sale of Spring Mobile to Prime Communications, cooperation agreement with activists Hestia Capital and Permit Capital, and exchange offer of outstanding senior notes; Kate Spade on its sale to Coach; Express on its takeover defense from Sycamore Partners; Coldwater Creek on its restructuring and sale of intellectual property to Sycamore Partners; and Henkel on its acquisition of Sun Products.

Chris received a Bachelor of Arts from University of Michigan in Behavioral Economics.

Links

Timeline

  • MD, New York

    Current role

View in org chart